Objectives: To define risk following systemic/intravascular administration of adipose-derived stromal vascular fraction (SVF) and cultured cells derived from SVF.
Introduction: The stromal vascular fraction of adipose tissue has considerable clinical potential due, in part, to the heterogeneity of its cellular composition. However, this population is derived by the digestion of a three dimensional tissue (adipose). This creates special concerns when the cell product is to be delivered into the vascular system with the consequent risk of embolism and stimulation of platelet aggregation.
Materials / method: Not applicable
Results: Risks derive from both byproducts of tissue disaggregation and from the cells themselves. By-products with risk include: tissue aggregates from incomplete disaggregation; collagen fragments; extracellular lipids; and extracellular DNA. SVF cells include vascular endothelial cells, smooth muscle cells, fibroblasts, stem cells, and leukocytes. Some of these cell types express Tissue Factor which plays a key role in the clotting process. Tissue Factor is also highly expressed in cultured cell populations derived from SVF, in particular, adipose-derived stem or stromal cells (ADSCs).
Conclusion: Systemic administration of SVF or cells derived by culture of SVF must take each of these risks into consideration and apply systems and processes by which risk is eliminated or managed, the success of these approaches in adequately mitigating these risks must also be demonstrated in in vivo preclinical testing before the SVF or SVF-derived product may be used clinically.
利益冲突声明
您有否接受任何资金来支持研究这个主题?
否
您是否接受过关于这项研究的任何酬金或其他报酬?
否
你是否和任何与您的研究所涉及的药物,材料或工具有密切联系的实体存在财务关系?
是
请注明名称(个人,公司,学会等等): Cytori KK (Japan; Consultant)
你是否拥有或者您已经为您此研究中的工具,药物或材料申请任何专利?
否
这项工作没有任何直接或间接的资金支持。由作者自己承担责任。